A significant and increasingly common trend observed in pediatric sleep clinics is the frequent, and often unsupervised, use of melatonin by children. While melatonin is a valuable tool in managing sleep disorders in pediatric populations and is often perceived as entirely safe due to its natural origins, its pervasive use has become a source of growing concern for medical professionals. Alongside melatonin, magnesium supplementation has also seen a surge in popularity for children’s sleep, though robust scientific evidence supporting its efficacy in this demographic remains limited, as detailed in comprehensive reviews on the topic.
The precise prevalence of melatonin use among children is difficult to quantify definitively. However, broader trends suggest a substantial increase. A 2022 study published in JAMA estimated that adult melatonin use had tripled between 2005 and 2018, with a concurrent rise in the dosages employed. This upward trajectory is mirrored in the pediatric market, where melatonin products are being aggressively marketed. This aggressive promotion, coupled with the drug’s widespread availability, has led to a concerning pattern of parents potentially using melatonin as a shortcut to address sleep difficulties, rather than prioritizing foundational sleep hygiene practices. Anecdotal evidence from online platforms, such as customer reviews on e-commerce sites, highlights this sentiment. One father, in a review quoted in a Wall Street Journal article that also cited significant sales figures for melatonin, candidly admitted, "my wife and I should do a better job starting the bedtime routine earlier, turning off the TV earlier, limiting sweets, etc., etc. Well, for whatever reason, this is not our strong suit. This 1 mg light dosage of melatonin is very helpful winding our kids down and getting them ready for bed." This sentiment underscores the perceived convenience of melatonin as a solution for parental challenges with establishing consistent sleep routines.
To provide a concise overview of the issue, a brief video explanation is available, addressing common inquiries regarding melatonin’s role in pediatric sleep.
The Escalating Use of Melatonin in Children
Estimates regarding the frequency of melatonin use in children vary, but available data indicates a significant rise. A New York Times article from May 2020, "Parents Are Relying on Melatonin to Help Their Kids Sleep. Should They?", reported an 87% increase in overall melatonin sales in the year preceding March 2020. A survey conducted by the Times involving 933 parents of children under 18 revealed that one-third of these children had experienced sleep difficulties in the past year, with over half of the parents reporting having administered melatonin to their children at some point.
More recent global data paints an even more stark picture. Scandinavia has witnessed an almost 500% increase in melatonin prescriptions. In the United States, melatonin has become the most common cause of overdose in pediatric emergency rooms and a frequent reason for calls to poison control centers. This widespread issue appears to be a global phenomenon, prompting increased scrutiny from healthcare providers and regulatory bodies.
Understanding Melatonin: Its Nature and Function
Melatonin is a naturally occurring hormone produced by the pineal gland in the brain. It functions as a chronobiotic agent, meaning it plays a crucial role in regulating the body’s circadian rhythm, or internal biological clock. At higher concentrations, it can also exhibit hypnotic properties, inducing sleep. However, it is essential to distinguish between these two primary effects. While the chronobiotic effect of melatonin is present in all individuals, its hypnotic effect is not universally experienced and is dose-dependent.
The natural surge in melatonin levels typically occurs one to three hours before sleep onset, a phenomenon known as the "dim light melatonin onset" (DLMO). This physiological signal marks the body’s preparation for sleep and is intrinsically linked to the circadian system’s wakefulness signals. In children experiencing insomnia, particularly those with difficulty initiating sleep, melatonin may be administered after their scheduled bedtime has passed, indicating that their bodies are not yet physiologically ready for sleep. This is one reason why behavioral interventions like "bedtime fading," which aligns bedtime with the child’s natural sleep readiness, can be highly effective. Clinical doses of melatonin, often ranging from 0.5 mg to 10 mg or higher, significantly exceed the physiological amounts naturally secreted by the body.
Further insights into the timing of melatonin administration are crucial for its effective use, as detailed in a supplementary video resource.
Efficacy of Melatonin for Pediatric Sleep Disturbions
The reported benefits of melatonin for children’s sleep typically include a reduction in the time it takes to fall asleep and an increase in overall sleep duration. However, like many medications used to address pediatric sleep issues, comprehensive and long-term research data is relatively limited. Most studies involve small cohorts followed for short durations. A significant contributing factor to this data gap is that melatonin is regulated as a dietary supplement by the U.S. Food and Drug Administration (FDA), rather than as a pharmaceutical. This regulatory classification means that large-scale, long-term efficacy and safety studies, often bankrolled by pharmaceutical companies for prescription drugs, are less common for melatonin. The regulatory framework governing supplements, established by the Dietary Supplement Health and Education Act of 1994, differs substantially from that for pharmaceuticals.
For a thorough review of the existing literature and evidence-based dosing recommendations, the International Pediatric Sleep Association (IPSA) offers valuable resources, including parent guides in multiple languages and literature reviews on melatonin use in both typically developing children and those with autism spectrum disorder.
The overarching consensus from current research suggests that melatonin can contribute to approximately 30 minutes of additional sleep per night, primarily by shortening the time it takes to fall asleep. While this effect is consistent across many trials, it is crucial to understand that melatonin is not a panacea for sleep problems.
To provide a more robust analysis, meta-analyses—studies that combine data from multiple independent research efforts—are often employed to assess the quality and consistency of findings.
Chronic Sleep-Onset Insomnia in Typically Developing Children
Difficulties in falling asleep are a common complaint among children, mirroring the challenges faced by adults. Chronic insomnia is clinically defined as a persistent struggle to fall asleep or stay asleep, occurring at least three times per week for three months or more, leading to dissatisfaction with sleep quality or noticeable daytime impairments.
A 2023 meta-analysis by Edemann-Callesen, which aggregated data from 419 children, reported an approximate 30-minute increase in total sleep time per night. Of this increase, about 18 minutes were attributed to a reduction in the time taken to fall asleep (sleep latency). Notably, this study found no significant improvement in daytime functioning and observed an increase in adverse events among children receiving melatonin compared to those in the placebo group.
The 2025 IPSA position paper on melatonin use in typically developing children offers important recommendations for this age group, emphasizing a cautious and evidence-based approach.
Autism Spectrum Disorder (ASD) and Melatonin
Sleep disturbances are a hallmark characteristic of Autism Spectrum Disorder (ASD). These issues can manifest as prolonged sleep onset latency, reduced total sleep time, and frequent awakenings during the night or in the early morning. Some research indicates that children with ASD may exhibit lower baseline levels of melatonin and reduced diurnal variation in its secretion. Consequently, melatonin has been frequently employed in this population, with studies generally reporting improvements in sleep onset and duration. Research has explored both immediate-release and extended-release formulations of melatonin, with the majority of studies administering doses 30 to 60 minutes prior to bedtime.
A 2025 meta-analysis by Yang et al. indicated that the most significant benefits of melatonin in children with ASD were observed in sleep efficiency (the ratio of time asleep to time in bed) and total sleep time, rather than sleep latency. The effectiveness of melatonin was found to be more pronounced in older children, with benefits decreasing in younger age groups. Some studies noted a potential for diminished effectiveness over time. Higher doses appeared to be more efficacious than lower doses in certain contexts.
A 2017 trial investigated a time-released melatonin preparation, PedPRM, at doses of 2-5 mg. Children receiving this formulation experienced an average of 57.5 minutes more sleep compared to the control group, with most of the benefit attributed to a reduction in sleep latency (falling asleep an average of 39 minutes faster). This medication, known as Slenyto in Europe, has unfortunately not yet received FDA approval in the United States.
The 2024 IPSA recommendations for managing insomnia in children with ASD provide guidance on melatonin use, underscoring the importance of a structured approach.
A 2020 guideline from the American Academy of Neurology, authored by Buckley et al., also advocates for prioritizing behavioral interventions before considering pharmacological options. The guideline suggests a tiered approach, beginning with short-acting melatonin and progressing to long-acting formulations if necessary, with initial doses of 2 mg, potentially increasing to a maximum of 10 mg.
In line with these recommendations, melatonin should be integrated into a comprehensive behavioral management plan. For pediatricians, practice pathways often suggest medication as an adjunct only after behavioral interventions have proven insufficient. Resources such as the Autism Speaks Sleep Toolkit and the book "Solving Sleep Problems in Children with Autism Spectrum Disorders: A Guide for Frazzled Families" offer valuable support for families navigating these challenges.
Attention-Deficit/Hyperactivity Disorder (ADHD) and Melatonin
Attention-deficit/hyperactivity disorder (ADHD) is frequently associated with sleep disturbances, and conversely, poor sleep can exacerbate attentional and behavioral issues. Early descriptions of ADHD, then referred to as "hyperkinetic disorder," acknowledged the profound impact of sleep problems on affected children and their families. One seminal paper noted, "Generally, the parents of hyperkinetic children [who would currently be referred to as children with ADHD] are so desperate over the night problems that the daytime ones pale in significance."
Up to 70% of children with ADHD may experience sleep problems, including difficulty falling asleep, alterations in sleep architecture, and daytime sleepiness.
A 2024 review article by Cortese on the management of sleep issues in ADHD highlighted two randomized controlled trials demonstrating positive effects. A 2024 systematic review by Larsson indicated a 30-minute decrease in sleep latency and improved sleep efficiency, although it found no evidence of improvement in quality of life or daytime ADHD symptoms. A small trial also suggested that melatonin might be beneficial for children with ADHD on stimulant medication experiencing insomnia, though this finding was based on chart review.
Delayed Sleep-Phase Syndrome (DSPS) and Melatonin
Delayed Sleep-Phase Syndrome (DSPS) is a common circadian rhythm disorder in adolescents, characterized by a significant shift in the natural sleep-wake cycle to later times than socially or academically required. Teens with DSPS often struggle to fall asleep before 1-2 AM or even later, leading to chronic sleep deprivation. Melatonin plays a well-established role in managing DSPS. Administering low doses several hours before the intended sleep onset, in conjunction with light exposure management, sleep hygiene practices, and gradual schedule adjustments (chronotherapy), can effectively reset the sleep period. The underlying issue in DSPS is a delayed DLMO, which melatonin can help advance. For children with DSPS, a recommended approach involves giving a dose 4-6 hours before their current usual sleep onset time, gradually advancing this by 4-5 days, using low-dose preparations. Among the conditions discussed, DSPS demonstrates the clearest and most consistent benefit from melatonin therapy.
Children With Neurodevelopmental Delay and Melatonin
Children with various forms of neurodevelopmental delay frequently experience significant insomnia. Melatonin may offer relief, but in some cases, its use has been associated with persistently elevated daytime melatonin blood levels, leading to daytime sleepiness. A 2023 review by Edemann-Callesen examined melatonin use across a range of conditions, including atopic dermatitis, epilepsy, intellectual disability, and specific genetic disorders. The study reported a modest increase in total sleep time (approximately 19 minutes, primarily due to reduced sleep latency), but found no evidence of subjective sleep improvement or enhanced daytime functioning.
Blindness and Melatonin
Some children with blindness experience disruptions in their sleep-wake cycles due to the lack of light cues to regulate their circadian rhythms. While small trials in adults have shown some benefit, the data concerning melatonin’s efficacy in visually impaired children is very limited.
Eczema and Melatonin
Eczema, characterized by dry, itchy skin, can lead to sleep disturbances and non-restorative sleep in children. Some research suggests a correlation between eczema and lower melatonin levels, and a recent trial indicated that melatonin supplementation might be beneficial for these children.
Critical Concerns Regarding Melatonin Use in Children
Despite its perceived safety and widespread use, several areas warrant significant concern regarding melatonin administration in children. These include potential known and theoretical side effects, as well as issues related to product preparation and regulation.
Side Effects (Theoretical and Observed): A primary theoretical concern is that the exogenous administration of melatonin to children could lead to persistently elevated blood melatonin levels throughout the day. This could result in ongoing daytime sleepiness, though the full spectrum of long-term effects remains unclear. It is crucial to reiterate that melatonin has not undergone the same rigorous testing as pharmaceutical drugs due to its classification as a dietary supplement by the FDA. Long-term studies on children using melatonin have largely relied on parental reports rather than objective biochemical measurements. Dr. David Kennaway, a physician from Australia, has published editorials highlighting the inadequacy of available long-term safety data for children. His perspective underscores that "melatonin is not registered for use in children, no rigorous long-term safety studies have been conducted in children and by the way melatonin is also a registered veterinary drug used to alter the reproduction of sheep and goats."
This lack of extensive clinical trials means that there is substantially less regulatory oversight concerning both the safety and efficacy of melatonin preparations for children. Furthermore, the labeling of many melatonin products can be misleading. For instance, a liquid preparation labeled as "1 mg" might actually contain 0.25 mg per dropperful, requiring parents to consult online resources or package inserts for accurate dosing information, which are often overlooked.
A 2020 study that followed 80 children for two years using the extended-release melatonin formulation PedPRM reported no evidence of adverse effects on weight, height, body mass index, or Tanner staging (a measure of sexual development). While this study offers some reassurance regarding long-term safety, the call for more extensive long-term research persists.
Addressing Existing Melatonin Use
For parents whose children are already taking melatonin, a measured approach is recommended. While there is little concrete evidence of significant harm, discussing the necessity of continued use with a pediatrician is paramount, especially if the medication was initiated without medical consultation. If a child has been using melatonin long-term and is sleeping well, a gradual dose reduction or transitioning to "as-needed" use, rather than nightly administration, can be considered. Emphasis should be placed on reinforcing robust sleep hygiene practices, including a consistent and high-quality bedtime routine and avoiding screen time for at least an hour before bed. The 2025 IPSA recommendations suggest limiting melatonin use to 3-6 months and periodically attempting to discontinue it.
Ensuring safe storage of melatonin and accurate dosing are critical to prevent accidental overdose or interactions with other medications.
Considerations for Melatonin Administration Under Medical Guidance
When a pediatrician and parent collaboratively decide on melatonin use, several factors regarding administration timing and dosage are crucial. The efficacy of melatonin can be significantly influenced by when it is administered relative to the child’s usual sleep schedule. A low dose given a few hours before bedtime may be more effective than a higher dose given at bedtime. Generally, 30-60 minutes before bedtime is considered an optimal window, though earlier administration may be beneficial in some cases.
The 2025 IPSA guidelines provide age-based dosing recommendations. The general approach is to start with a low dose, such as 0.5 mg, and increase it weekly by 0.5 mg until improvement is observed or the maximum recommended dose for the child’s age is reached.
A comprehensive melatonin dosing calculator for children, based on the latest guidelines, can assist parents and healthcare providers in determining the safest dosage.
Crucially, melatonin should never be viewed as a substitute for sound sleep hygiene practices. It should be integrated into a comprehensive approach that includes a high-quality bedtime routine, mindful light exposure management, and an appropriate sleep schedule.
When possible, opting for USP Verified preparations may offer an added layer of assurance regarding product quality and manufacturing standards, as these products are tested by the U.S. Pharmacopeial Convention.
The Takeaway: Should Children Take Melatonin?
The decision to medicate a child for sleep issues is often fraught with parental deliberation, typically undertaken after exhausting behavioral interventions. The limited availability of FDA-approved insomnia medications for children, with chloral hydrate being largely unavailable, often leads to the consideration of melatonin.
While acknowledging the concerns raised by experts regarding the long-term safety data, many clinicians, including those specializing in pediatric sleep, frequently utilize melatonin in their practice. It can be a highly effective tool for certain children and families, particularly those facing significant sleep challenges that impact daily functioning. The potential consequences of chronic poor sleep on a child’s development and family well-being are considerable. Therefore, for some children, especially those with autism or developmental disorders who may have more complex sleep architecture, melatonin can be a valuable therapeutic option.
The primary goal of any sleep intervention, whether behavioral or pharmacological, is to achieve healthy sleep with minimal medication. Melatonin may be a suitable option for a child if:
- Behavioral interventions have been thoroughly attempted and have proven insufficient.
- The child has a diagnosed sleep disorder for which melatonin is indicated.
- The decision is made in consultation with a qualified healthcare provider who can monitor its use and effectiveness.
In instances where sleep difficulties emerge suddenly, it is important to consider the possibility of a sleep regression, for which specific management strategies exist.
The journey toward resolving pediatric sleep issues is multifaceted, and while melatonin offers a potential avenue for relief, it must be approached with informed caution, prioritizing established sleep hygiene and ongoing medical guidance.
